The launch of the Retatrutide vial signifies a potential advance in the approach to body regulation. This innovative therapy combines two mechanisms – stimulation of the GLP-1 target and blocking of the DPP-4 process – suggesting a distinctive strategy for tackling obesity . Early clinical result